Endoscope Reprocessing Market: as rising GI procedure volumes driven by colorectal cancer screening expansion to age 45 compound per-cycle HLD chemistry and AER machine capacity demand so the Joint Commission 2024 real-time compliance documentation mandate creates a premium product tier for digitally verified reprocessing ecosystems integrating RFID scope tracking with chain-of-custody audit records, and so STERIS acquires Integrated Medical Systems in December 2024 to extend its reprocessing portfolio from AER and chemistry through drying cabinet management while Olympus opens the Sapphire On-Demand sterile endoscope facility in Melbourne as an outsourced sterilisation service model that generates per-scope service revenue as an alternative to hospital-owned AER capital infrastructure.

The global endoscope reprocessing market size was USD 2.26 Billion in 2025 and is expected to register a revenue CAGR of 8.5% during the forecast period. Market revenue growth is driven by factors such as the rising GI endoscopy procedure volumes driven by colorectal cancer screening guideline expansion to age 45 that compound per-cycle HLD chemistry and AER machine capacity demand, the progressive integration of digital compliance documentation into AER systems creating a premium product tier above standalone capital equipment that commands higher per-installation revenue, as well as the growing single-use disposable endoscope adoption in bronchoscopy and urology that creates a mixed signal for reprocessing revenue by eliminating per-procedure consumable demand in converting departments while core GI endoscopy reprocessing remains at full volume. The first driving factor is the GI endoscopy procedure volume expansion following the US Preventive Services Task Force 2021 recommendation extending colorectal cancer screening initiation to age 45 from the prior age 50 recommendation, expanding the addressable colonoscopy screening population by approximately 20 million Americans and creating sustained annual procedure volume growth requiring proportional reprocessing consumable demand. Each additional GI endoscopy procedure generates approximately USD 3 to USD 8 in HLD chemistry consumption and USD 1 to USD 4 in enzymatic pre-cleaning detergent consumption, creating a tightly correlated relationship between endoscopy procedure volume growth and reprocessing consumable revenue that STERIS documented through 14% Healthcare segment consumable revenue growth in Q4 fiscal 2024 with service revenue growing 9% over the same period. The second driving factor is the Joint Commission 2024 revised standards mandating real-time documentation of every HLD cycle creating demand for AER systems with automatic electronic compliance record generation. The third driving factor is the expanding digitally verified reprocessing ecosystem market, where STERIS's December 2024 acquisition of Integrated Medical Systems adds drying cabinet and endoscope storage management to its AER and chemistry portfolio, enabling chain-of-custody compliance documentation from reprocessing basin through drying cabinet storage to procedure room retrieval in a single managed workflow. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way each AER installation generates multi-component recurring revenue through service contract fees, cycle chemistry consumable refills, filter replacements, and cycle verification test strip consumption that compounds over the 7 to 12 year AER service life at each installed hospital endoscopy department, creating a durable installed base revenue stream that grows with test strip consumption volume at each installed system as endoscopy procedure volume expands. Once a hospital endoscopy department has installed an AER and validated the chemistry and cycle parameters per FDA and ISO 15883 requirements, the AER generates annual service contract revenue, quarterly filter replacement revenue, and per-cycle chemistry consumable revenue at rates tied directly to daily reprocessing volume, so each incremental endoscopy procedure performed at that department adds consumable revenue without requiring a new AER capital sale. As a result, the reprocessing market revenue trajectory is more dependent on per-cycle consumable volume growth at the installed AER base than on new AER capital placement rate, and the forecast tilts toward STERIS and Olympus as the providers with the largest installed AER base generating the highest recurring consumable and service revenue rather than toward new market entrants with competitive AER specifications but smaller installed revenue base positions. For instance, in September 2024, Olympus opened Sapphire, its first flexible endoscope sterilisation facility in Melbourne as part of the Olympus On-Demand model delivering sterile ready-to-use flexible endoscopes to Australian hospitals, creating a service revenue alternative to hospital-owned AER infrastructure that generates per-scope revenue from Olympus's centralised sterilisation facility rather than per-cycle consumable revenue from a hospital-installed AER machine. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the tightly correlated relationship between GI endoscopy procedure volume growth and reprocessing consumable revenue, where each additional colonoscopy, gastroscopy, or ERCP procedure generates approximately USD 3 to USD 8 in HLD chemistry consumption and USD 1 to USD 4 in enzymatic pre-cleaning detergent consumption at the endoscopy suite reprocessing station, creating a revenue compound that grows with procedure volume independent of new AER capital placements. More than 20 million gastrointestinal endoscopy procedures are performed annually in the United States per US DHHS data, a volume that has grown with the 2021 USPSTF recommendation extending colorectal cancer screening initiation to age 45, expanding the addressable colonoscopy screening population by approximately 20 million Americans and creating sustained per-year procedure volume growth requiring proportional reprocessing consumable demand. STERIS plc reported that its Healthcare segment consumable revenue grew 14% in Q4 fiscal 2024 and service revenue grew 9%, driven by procedure volumes in the US and price and market share gains in endoscopy reprocessing consumables, confirming the commercial significance of procedural volume growth as a consumable revenue driver for the endoscope reprocessing market leader. In October 2024, Olympus received CE mark approval under the Medical Device Regulation for three cloud-based AI medical devices forming the foundation of its Intelligent Endoscopy Ecosystem, with the integrated Hytrack RFID tracking system linking endoscope identification with the AI data platform for end-to-end reprocessing compliance and procedure outcome documentation. The effect on the market is a structural demand floor for reprocessing consumables that grows with GI endoscopy procedure volume regardless of the AER installed base age or new AER capital placement rate, providing durable consumable revenue growth that sustains the reprocessing market CAGR above the broader medical device market average. These are some of the key factors driving revenue growth of the market.

The second driver is the institutional demand created by the Joint Commission 2024 real-time HLD documentation mandate for endoscope reprocessing compliance systems that automatically associate scope identity with cycle parameters and operator identification, capabilities that standalone AER systems without RFID integration cannot provide without supplemental tracking system investment. STERIS's December 2024 acquisition of Integrated Medical Systems adds drying cabinet and endoscope storage management to STERIS's AER and cleaning chemistry portfolio, enabling STERIS to offer chain-of-custody compliance documentation from the reprocessing basin through drying cabinet storage to procedure room retrieval in a single managed workflow at a premium total system revenue per account above standalone AER and chemistry supply. Olympus Corporation's Hytrack RFID system, integrated with the ETD washer-disinfector and the EVIS X1 endoscopy system, creates a closed-loop reprocessing intelligence ecosystem where each scope's service history, cycle count, and repair timeline are accessible through a unified data platform, positioning Olympus as the provider of the most complete endoscope lifecycle intelligence system. The June 2024 Getinge launch of the Poladus 150 low-temperature steriliser for heat-sensitive endoscopes addresses the subset of flexible endoscopes requiring sterilisation rather than HLD, such as those used in sterile field procedures or at centres with sterilisation-level protocols, providing a premium reprocessing product above HLD-based AER systems in the cycle efficacy hierarchy. The effect on the market is a premium product tier that generates higher per-account total revenue through combined AER capital, service contract, tracking software licence, drying cabinet, and chemistry consumable revenue from an integrated reprocessing ecosystem rather than standalone AER and chemistry procurement at each installation. These are some of the key factors driving revenue growth of the market.

STERIS's December 2024 acquisition of Integrated Medical Systems, adding drying cabinet and endoscope storage management to the STERIS AER and HLD chemistry portfolio, enables a single-vendor chain-of-custody documentation model covering scope retrieval from procedure room through reprocessing, drying cabinet storage, and return to next endoscopist. The Joint Commission 2024 real-time HLD documentation mandate creates institutional demand for this integrated accountability model that standalone AER and chemistry vendors without storage management capability cannot match at audit.

The third driver is the geographic and service model expansion of the endoscope reprocessing market through Olympus's outsourced sterile endoscope delivery service and the Chinese NHC 2024 infection control mandates driving AER capital procurement at tier-2 hospitals. In September 2024, Olympus Australia opened Sapphire, its first flexible endoscope sterilisation facility in Melbourne, operating as part of the Olympus On-Demand model that delivers sterile ready-to-use flexible endoscopes directly to subscribing Australian hospital endoscopy departments, reducing hospital reprocessing infrastructure requirements and creating per-scope recurring service revenue for Olympus's centralised sterilisation operation as an alternative revenue model to selling AER capital equipment and chemistry consumables to hospital-owned reprocessing facilities. China's National Health Commission 2024 infection control directives mandating standardised AER reprocessing at the estimated 24,000 licensed endoscopy centres create sustained AER and HLD chemistry demand across Chinese hospital tiers, with Shinva Medical Instrument Co. and Sanqiang Medical Equipment serving the domestic mid-market with cost-competitive automated reprocessing systems that expand AER penetration from tier-1 urban hospitals into tier-2 and tier-3 hospital endoscopy departments. Brazil's ANVISA 2024 ISO 15883 harmonisation creates standardised automated reprocessing requirements at Brazilian hospital endoscopy departments, generating AER procurement demand at facilities transitioning from manual to automated reprocessing under the new national compliance framework. The effect on the market is a combined expansion of the reprocessing revenue opportunity through service model innovation at established market accounts and geographic AER penetration growth at emerging market hospital settings that are transitioning from manual to automated reprocessing under national regulatory mandate frameworks. These are some of the key factors driving revenue growth of the market.

However, the endoscope reprocessing market faces adoption constraints from single-use disposable endoscope conversion in bronchoscopy and urology, AER capital cost barriers, and regulatory divergence that collectively limit revenue growth below the underlying GI procedure volume expansion rate. Because Ambu A/S reported 15.4% organic endoscopy growth in FY2024/25 and the June 2025 FDA clearance of the aScope 5 Cysto HD for PCNL expanded single-use penetration into complex kidney stone procedures, each bronchoscopy or ureteroscopy department converting to single-use eliminates per-procedure HLD chemistry, detergent, and AER machine cycle revenue at converting facilities, creating a revenue substitution dynamic that reduces total reprocessing consumable revenue per procedure episode even as total endoscopy procedure counts grow. AER capital cost of USD 80,000 to USD 200,000 per installation creates procurement barriers at community hospitals and outpatient GI centres where manual reprocessing remains the operational standard despite higher compliance risk, limiting AER penetration rate at the large number of smaller endoscopy facilities below the procedure volume threshold that justifies AER capital investment relative to manual reprocessing labour and chemistry cost. Regulatory divergence between FDA endoscope reprocessing guidance, ISO 15883 international standards, and national health authority requirements across European, Asia Pacific, and Latin American markets creates compliance complexity for multinational hospital networks and AER manufacturers maintaining multiple market-specific validation documentation packages, extending procurement approval timelines and increasing per-market regulatory compliance costs. These factors substantially limit endoscope reprocessing market growth over the forecast period.

Based on product, the global endoscope reprocessing market is segmented into automated endoscope reprocessors, high-level disinfectants and test strips, detergents and pre-cleaning products, and drying and storage and transport and tracking systems. Automated endoscope reprocessors hold the largest revenue share at approximately 38% of 2025 market revenue, combining capital equipment purchase at USD 40,000 to USD 200,000 per system, service contract revenue, cycle consumable chemistry refills and filter replacements, and cycle verification test strip consumption in a multi-component recurring revenue stream from each installed AER unit. STERIS, Olympus, Getinge, Wassenburg Medical, and SteelcoBelimed are the primary AER manufacturers. High-level disinfectants and test strips account for approximately 32% of market revenue and are expected to register the fastest revenue growth rate over the forecast period, driven by per-procedure HLD chemistry consumption growth tracking endoscopy procedure volume increases at approximately USD 3 to USD 8 per procedure cycle.

Based on endoscope type, the global endoscope reprocessing market is segmented into flexible GI endoscopes, flexible bronchoscopes and ureteroscopes, rigid endoscopes, and specialty endoscopes. Flexible GI endoscopes hold the largest reprocessing revenue share because colonoscopes, gastroscopes, duodenoscopes, and ERCP scopes are the highest-volume reprocessable flexible endoscopes, with over 20 million GI endoscopy procedures annually in the US alone generating the highest HLD chemistry and AER machine cycle demand of any endoscope category. The flexible bronchoscopes and ureteroscopes segment faces the most significant single-use conversion pressure, with Ambu A/S FY2024/25 15.4% organic growth and the aScope 5 Cysto HD PCNL FDA clearance in June 2025 expanding single-use format penetration in both ureteroscopy and cystoscopy applications, reducing reprocessing consumable revenue per procedure in converting departments.

Based on regional analysis, the endoscope reprocessing market in North America accounted for largest revenue share in 2025. The United States leads through the highest GI endoscopy procedure volume globally at over 20 million procedures annually, STERIS's dominant US market position in AER and HLD chemistry supply with US revenues of USD 3.75 billion in fiscal 2024, and the Joint Commission 2024 real-time HLD documentation mandate creating procurement urgency for digital-compliance-capable AER systems. In January 2025, STERIS Hong Kong Limited won a HKD 1.44 million contract to supply liquid germicide disinfectors and flexible endoscopes for Grantham Hospital redevelopment, demonstrating STERIS's Asia Pacific commercial expansion alongside its dominant North American position.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, France, and Scandinavia represent the four largest national endoscope reprocessing markets. The June 2024 SteelcoBelimed joint venture combining Steelco's Italian washer-disinfector manufacturing with Belimed's Swiss sterilisation engineering creates the largest European-headquartered reprocessing equipment platform with product breadth across AERs, instrument washers, and steam sterilisers for hospital CSSD and endoscopy suite procurement. The NHS GBP 4.1 billion endoscopy infrastructure programme drives AER procurement at NHS trust endoscopy units commissioning new capacity under national bowel cancer screening expansion. The European Centre for Disease Prevention and Control reporting over 3.5 million healthcare-associated infections annually from reusable devices sustains institutional reprocessing investment pressure. Getinge launched the Poladus 150 low-temperature steriliser in June 2024 for European life science and hospital markets addressing the premium sterilisation segment above standard HLD-based AER products.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period. Japan, China, South Korea, and Australia represent the four largest national endoscope reprocessing markets. In September 2024, Olympus Australia opened Sapphire in Melbourne as part of the Olympus On-Demand solution delivering sterile ready-to-use endoscopes to Australian hospitals, establishing the outsourced sterilisation service revenue model in Asia Pacific. China's NHC 2024 infection control directives mandating standardised reprocessing at 24,000 licensed endoscopy centres create sustained AER and HLD chemistry demand. Japan's 2022 JGES guidelines specifying AER use as the preferred flexible endoscope reprocessing method sustain AER procurement at approximately 14,800 Japanese gastrointestinal endoscopy facilities, leaving more room for Asia Pacific market growth than in North America where AER penetration at hospital endoscopy programmes is already higher.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national endoscope reprocessing markets. Brazil's ANVISA 2024 ISO 15883 harmonisation creating standardised automated reprocessing requirements at Brazilian hospital endoscopy departments generates AER and HLD chemistry procurement demand at facilities transitioning from manual to validated protocol-driven reprocessing. The indirect effects of Iran-US sanctions and Strait of Hormuz supply chain disruptions have maintained elevated costs for specialty chemical reagents and electronic AER system components entering Brazilian and Mexican healthcare supply chains through affected trade routes through 2026, raising the total acquisition cost of HLD chemistry and AER installations at Latin American hospital endoscopy departments.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary GCC markets. STERIS demonstrated active GCC commercial presence through the January 2025 STERIS Hong Kong contract for liquid germicide disinfectors at Grantham Hospital redevelopment, and Saudi Vision 2030 hospital construction programmes creating new tertiary hospital facilities each requiring complete endoscopy reprocessing infrastructure generate sustained AER capital equipment and HLD chemistry procurement demand at newly commissioned hospital endoscopy departments. South Africa is the most established sub-Saharan market for AER adoption at private hospital group endoscopy programmes.